Can Citicoline Be Given by IV Infusion?
Yes, citicoline (CDP-choline) can be administered by intravenous infusion and is rapidly absorbed with bioavailability approximately equivalent to oral administration.
Route of Administration and Pharmacokinetics
Citicoline can be safely administered through multiple parenteral routes, including intravenous infusion 1. The evidence demonstrates that:
- Bioavailability by IV route is virtually identical to oral administration, as absorption by the oral route is nearly complete 1
- IV citicoline is rapidly hydrolyzed after administration, with the unchanged compound becoming undetectable in plasma almost immediately after infusion ends 2
- Following IV infusion over 30 minutes in humans, plasma levels of the two main metabolites (choline and cytidine) peak at the end of infusion but remain significantly elevated for at least 6 hours 2
Clinical Applications and Dosing
The research literature documents extensive IV use of citicoline across multiple conditions:
Acute Stroke: While a large European trial (ICTUS) testing citicoline in 2,298 patients with moderate-to-severe ischemic stroke within 24 hours showed no benefit on 90-day outcomes 3, earlier meta-analyses suggested potential benefit in specific subgroups. The stroke guidelines note that citicoline has been "studied extensively" but did not demonstrate efficacy based on predetermined primary endpoints 4.
Experimental Dosing in Research: Studies have used IV doses ranging from:
- 100-500 mg/kg in animal models 5, 6, 7
- Human studies typically used lower doses, though specific dosing varies by indication 2
Safety Profile
Citicoline demonstrates a favorable safety profile across multiple studies 1, 8:
- No serious side effects reported in clinical series
- No significant systemic cholinergic effects
- Well-tolerated product with high tolerability
- In animal studies, repeated IV administration (250 mg/kg) was safe and showed tissue-protective effects 5
Important Caveats
The evidence does not support routine IV citicoline use for acute stroke based on the most recent and highest-quality evidence. The ICTUS trial (2011) - a large, multicenter randomized trial - was stopped prematurely for futility 3. This represents the strongest evidence against its use in acute ischemic stroke, despite earlier promising signals.
For other indications (head trauma, cognitive impairment, glaucoma), the evidence is mixed and primarily involves oral administration 1, 9. IV administration is feasible and safe, but clinical benefit remains uncertain for most neurological conditions outside of research settings.